Advertisement

Endocrine

pp 1–8 | Cite as

Circulating microRNA-144-3p and miR-762 are novel biomarkers of Graves’ disease

  • Qiuming Yao
  • Xuan Wang
  • Weiwei He
  • Zhenyu Song
  • Bin Wang
  • Jinan ZhangEmail author
  • Qiu QinEmail author
Original Article

Abstract

Purpose

Recently, it has been confirmed that circulating miRNAs play an important role in disease pathogenesis and can be biomarkers of many autoimmune diseases. However, the knowledge about circulating miRNAs in Graves’ disease (GD) is very limited. In this study, we aimed to identify circulating miRNAs as potential biomarkers of GD.

Methods

We recruited 68 participants who met the criteria for GD and healthy controls. The expression profile of miRNAs in plasma was detected using microarrays. We found five interesting miRNAs were differentially expressed between GD and control group and futher validated their relative expression by quantitative real-time PCR. According to their putative target genes predicted by the TargetScan database, we also performed Gene ontology (GO) and Kyoto encyclopedia of genes and genomes (KEGG) analyses to predict their potential functions and related pathways.

Results

Microarray data showed that five miRNAs were differentially expressed in GD and control plasma samples. Among them, miR-16-1-3p, miR-122-5p, miR-221-3p, and miR-762 were upregulated in GD (P < 0.001). In validation stage, we found miR-144-3p was significantly decreased and miR-762 was markedly upregulated in GD plasma (P < 0.01). In addition, miR-762 expression was positively associated with levels of FT3 (r = 0.307, P = 0.038) as well as TRAb (r = 0.302, P = 0.042). The receiver-operating characteristic (ROC) curve analysis showed that both miR-144-3p and miR-762 displayed good sensitivity and specificity in discriminating the GD patients from the rest of subjects with the area under the ROC curve (AUC) of 0.761 (P = 0.001, 95% CI = 0.648–0.875) and 0.737 (P = 0.001, 95% CI = 0.618–0.857), respectively. Combination of miR-144-3p and miR-762 could better discriminate GD patients from healthy controls with AUC of 0.861 (P < 0.001, 95% CI = 0.775–0.947).

Conclusions

We first demonstrated that aberrant levels of plasmic miR-144-3p and miR-762 were associated with GD, which may be biomarkers for GD diagnosis.

Keywords

Graves’ disease MicroRNA Plasma Biomarker 

Notes

Acknowledgements

The authors would like to thank all of the participants who took part in the studies.

Funding

This project was supported by grants from the National Natural Science Foundation of China (Nos 81670722 and 81873636), and Natural Science Foundation of Shanghai (18ZR1433800).

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval and consent to participate

This work was approved by the Ethics Committee of Jinshan Hospital, Fudan University. Written informed consents were obtained from all participants.

References

  1. 1.
    F. Shehjar, D. Afroze, R.A. Misgar, S.A. Malik, B.A. Laway, Association of FoxP3 promoter polymorphisms with the risk of Graves’ disease in ethnic Kashmiri population. Gene (2018).  https://doi.org/10.1016/j.gene.2018.06.023
  2. 2.
    L. Zhang, G. Masetti, G. Colucci, M. Salvi, D. Covelli, A. Eckstein, U. Kaiser, M.S. Draman, I. Muller, M. Ludgate, L. Lucini, F. Biscarini, Combining micro-RNA and protein sequencing to detect robust biomarkers for Graves’ disease and orbitopathy. Sci. Rep. 8, 8386 (2018)CrossRefGoogle Scholar
  3. 3.
    J. Kim, F. Yao, Z. Xiao, Y. Sun, L. Ma, MicroRNAs and metastasis: small RNAs play big roles. Cancer Metastas-. Rev. 37, 5–15 (2018)CrossRefGoogle Scholar
  4. 4.
    V. Ambros, The functions of animal microRNAs. Nature 431, 350–355 (2004)CrossRefGoogle Scholar
  5. 5.
    J. Massart, M. Katayama, A. Krook: microManaging glucose and lipid metabolism in skeletal muscle: Role of microRNAs. Biochim. Biophys. Acta 1861, 2130–2138 (2016)CrossRefGoogle Scholar
  6. 6.
    D.W. Trobaugh, W.B. Klimstra, MicroRNA regulation of RNA virus replication and pathogenesis. Trends Mol. Med. 23, 80–93 (2017)CrossRefGoogle Scholar
  7. 7.
    C. Xiao, K. Rajewsky, MicroRNA control in the immune system: basic principles. Cell 136, 26–36 (2009)CrossRefGoogle Scholar
  8. 8.
    K. Zen, C.Y. Zhang, Circulating microRNAs: a novel class of biomarkers to diagnose and monitor human cancers. Med. Res. Rev. 32, 326–348 (2012)CrossRefGoogle Scholar
  9. 9.
    J.A. Weber, D.H. Baxter, S. Zhang, D.Y. Huang, K.H. Huang, M.J. Lee, D.J. Galas, K. Wang, The microRNA spectrum in 12 body fluids. Clin. Chem. 56, 1733–1741 (2010)CrossRefGoogle Scholar
  10. 10.
    D. Zubakov, A.W. Boersma, Y. Choi, P.F. van Kuijk, E.A. Wiemer, M. Kayser, MicroRNA markers for forensic body fluid identification obtained from microarray screening and quantitative RT-PCR confirmation. Int. J. Leg. Med. 124, 217–226 (2010)CrossRefGoogle Scholar
  11. 11.
    L. Zeng, J. Cui, H. Wu, Q. Lu, The emerging role of circulating microRNAs as biomarkers in autoimmune diseases. Autoimmunity 47, 419–429 (2014)CrossRefGoogle Scholar
  12. 12.
    S. Mi, J. Zhang, W. Zhang, R.S. Huang, Circulating microRNAs as biomarkers for inflammatory diseases. Microrna 2, 63–71 (2013)CrossRefGoogle Scholar
  13. 13.
    C. Castro-Villegas, C. Perez-Sanchez, A. Escudero, I. Filipescu, M. Verdu, P. Ruiz-Limon, M.A. Aguirre, Y. Jimenez-Gomez, P. Font, A. Rodriguez-Ariza, J.R. Peinado, E. Collantes-Estevez, R. Gonzalez-Conejero, C. Martinez, N. Barbarroja, C. Lopez-Pedrera, Circulating miRNAs as potential biomarkers of therapy effectiveness in rheumatoid arthritis patients treated with anti-TNFalpha. Arthritis Res. Ther. 17, 49 (2015)CrossRefGoogle Scholar
  14. 14.
    R. Gandhi, B. Healy, T. Gholipour, S. Egorova, A. Musallam, M.S. Hussain, P. Nejad, B. Patel, H. Hei, S. Khoury, F. Quintana, P. Kivisakk, T. Chitnis, H.L. Weiner, Circulating microRNAs as biomarkers for disease staging in multiple sclerosis. Ann. Neurol. 73(6), 729–740 (2013)CrossRefGoogle Scholar
  15. 15.
    H. Yamada, M. Itoh, I. Hiratsuka, S. Hashimoto, Circulating microRNAs in autoimmune thyroid diseases. Clin. Endocrinol. (Oxf.). 81, 276–281 (2014)CrossRefGoogle Scholar
  16. 16.
    F. Wang, S.J. Zhang, X. Yao, D.M. Tian, K.Q. Zhang, D.M. She, F.F. Guo, Q.W. Zhai, H. Ying, Y. Xue, Circulating microRNA-1a is a biomarker of Graves’ disease patients with atrial fibrillation. Endocrine 57, 125–137 (2017)CrossRefGoogle Scholar
  17. 17.
    I. Hiratsuka, H. Yamada, E. Munetsuna, S. Hashimoto, M. Itoh, Circulating microRNAs in Graves’ disease in relation to clinical activity. Thyroid 26, 1431–1440 (2016)CrossRefGoogle Scholar
  18. 18.
    L. Zheng, C. Zhuang, X. Wang, L. Ming, Serum miR-146a, miR-155, and miR-210 as potential markers of Graves’ disease. J. Clin. Lab. Anal. 32 (2018).  https://doi.org/10.1002/jcla.22266
  19. 19.
    R. Martinez-Hernandez, M. Sampedro-Nunez, A. Serrano-Somavilla, A.M. Ramos-Levi, H. de la Fuente, J.C. Trivino, A. Sanz-Garcia, F. Sanchez-Madrid, M. Marazuela, A. MicroRNA, Signature for evaluation of risk and severity of autoimmune thyroid diseases. J. Clin. Endocrinol. Metab. 103, 1139–1150 (2018)CrossRefGoogle Scholar
  20. 20.
    M. Jiang, W. Ma, Y. Gao, K. Jia, Y. Zhang, H. Liu, Q. Sun, IL-22-induced miR-122-5p promotes keratinocyte proliferation by targeting Sprouty2. Exp. Dermatol. 26, 368–374 (2017)CrossRefGoogle Scholar
  21. 21.
    I. Selmaj, M. Cichalewska, M. Namiecinska, G. Galazka, W. Horzelski, K.W. Selmaj, M.P. Mycko, Global exosome transcriptome profiling reveals biomarkers for multiple sclerosis. Ann. Neurol. 81, 703–717 (2017)CrossRefGoogle Scholar
  22. 22.
    Y.J. Su, I.C. Lin, L. Wang, C.H. Lu, Y.L. Huang, H.C. Kuo, Next generation sequencing identifies miRNA-based biomarker panel for lupus nephritis. Oncotarget 9, 27911–27919 (2018)Google Scholar
  23. 23.
    M. Liguori, N. Nuzziello, F. Licciulli, A. Consiglio, M. Simone, R.G. Viterbo, T.M. Creanza, N. Ancona, C. Tortorella, L. Margari, G. Grillo, P. Giordano, S. Liuni, M. Trojano, Combined microRNA and mRNA expression analysis in pediatric multiple sclerosis: an integrated approach to uncover novel pathogenic mechanisms of the disease. Hum. Mol. Genet. 27, 66–79 (2018)CrossRefGoogle Scholar
  24. 24.
    F. Liu, N. Chen, R. Xiao, W. Wang, Z. Pan, miR-144-3p serves as a tumor suppressor for renal cell carcinoma and inhibits its invasion and metastasis by targeting MAP3K8. Biochem. Biophys. Res. Commun. 480, 87–93 (2016)CrossRefGoogle Scholar
  25. 25.
    Z.X. Cheng, Y.X. Song, Z.Y. Wang, Y. Wang, Y. Dong, miR-144-3p serves as a tumor suppressor by targeting FZD7 and predicts the prognosis of human glioblastoma. Eur. Rev. Med. Pharmacol. Sci. 21, 4079–4086 (2017)Google Scholar
  26. 26.
    C. Wu, B. Xu, Y. Zhou, M. Ji, D. Zhang, J. Jiang, C. Wu, Correlation between serum IL-1beta and miR-144-3p as well as their prognostic values in LUAD and LUSC patients. Oncotarget 7, 85876–85887 (2016)Google Scholar
  27. 27.
    M. Wu, C. Huang, X. Huang, R. Liang, Y. Feng, X. Luo, MicroRNA-144-3p suppresses tumor growth and angiogenesis by targeting SGK3 in hepatocellular carcinoma. Oncol. Rep. 38, 2173–2181 (2017)CrossRefGoogle Scholar
  28. 28.
    Y. Zhao, Z. Xie, J. Lin, P. Liu, MiR-144-3p inhibits cell proliferation and induces apoptosis in multiple myeloma by targeting c-Met. Am. J. Transl. Res. 9, 2437–2446 (2017)Google Scholar
  29. 29.
    B. Zuo, J. Zhai, L. You, Y. Zhao, J. Yang, Z. Weng, L. Dai, Q. Wu, C. Ruan, Y. He, Plasma microRNAs characterising patients with immune thrombocytopenic purpura. Thromb. Haemost. 117, 1420–1431 (2017)CrossRefGoogle Scholar
  30. 30.
    Y. Li, R. Huang, L. Wang, J. Hao, Q. Zhang, R. Ling, J. Yun, microRNA-762 promotes breast cancer cell proliferation and invasion by targeting IRF7 expression. Cell. Prolif. 48, 643–649 (2015)CrossRefGoogle Scholar
  31. 31.
    A. Paun, P.M. Pitha, The IRF family, revisited. Biochimie 89, 744–753 (2007)CrossRefGoogle Scholar
  32. 32.
    K. Honda, T. Taniguchi, IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat. Rev. Immunol. 6, 644–658 (2006)CrossRefGoogle Scholar
  33. 33.
    M.W. Russo, M.W. Fried, Side effects of therapy for chronic hepatitis C. Gastroenterology 124, 1711–1719 (2003)CrossRefGoogle Scholar
  34. 34.
    P. Burman, T.H. Totterman, K. Oberg, F.A. Karlsson, Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon. J. Clin. Endocrinol. Metab. 63, 1086–1090 (1986)CrossRefGoogle Scholar
  35. 35.
    D.S. Ross, H.B. Burch, D.S. Cooper, M.C. Greenlee, P. Laurberg, A.L. Maia, S.A. Rivkees, M. Samuels, J.A. Sosa, M.N. Stan, M.A. Walter, 2016 American thyroid association guidelines for diagnosis and management of hyperthyroidism and other causes of thyrotoxicosis. Thyroid 26, 1343–1421 (2016)CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Department of EndocrinologyJinshan Hospital of Fudan UniversityShanghaiChina
  2. 2.Department of EndocrinologyAffiliated Hospital of Yanan UniversityShanxiChina
  3. 3.Department of UrologyJinshan Hospital of Fudan UniversityShanghaiChina
  4. 4.Department of EndocrinologyShanghai University of Medicine & Health Sciences Affiliated Zhoupu HospitalShanghaiChina

Personalised recommendations